DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $12.3333.

Several equities analysts recently commented on DMAC shares. Lake Street Capital restated a “buy” rating on shares of DiaMedica Therapeutics in a research report on Monday, January 5th. Wall Street Zen cut DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, January 21st. Cantor Fitzgerald initiated coverage on shares of DiaMedica Therapeutics in a report on Friday, November 14th. They set an “overweight” rating for the company. Finally, TD Cowen initiated coverage on shares of DiaMedica Therapeutics in a research note on Thursday, October 30th. They set a “buy” rating on the stock.

DiaMedica Therapeutics Stock Performance

Shares of DiaMedica Therapeutics stock opened at $8.14 on Friday. The firm has a market cap of $423.93 million, a P/E ratio of -11.46 and a beta of 1.11. The firm’s 50-day simple moving average is $8.36 and its 200-day simple moving average is $7.06. DiaMedica Therapeutics has a twelve month low of $3.19 and a twelve month high of $10.42.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). On average, equities analysts forecast that DiaMedica Therapeutics will post -0.59 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DiaMedica Therapeutics news, major shareholder Jan Stahlberg acquired 73,099 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was purchased at an average price of $8.57 per share, for a total transaction of $626,458.43. Following the transaction, the insider owned 8,825,742 shares in the company, valued at $75,636,608.94. This trade represents a 0.84% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders acquired 1,061,277 shares of company stock worth $7,632,627. Company insiders own 7.30% of the company’s stock.

Institutional Trading of DiaMedica Therapeutics

Several large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. bought a new position in shares of DiaMedica Therapeutics in the third quarter valued at about $27,000. China Universal Asset Management Co. Ltd. acquired a new stake in DiaMedica Therapeutics in the 4th quarter valued at about $29,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of DiaMedica Therapeutics in the second quarter worth about $29,000. Bank of America Corp DE lifted its position in shares of DiaMedica Therapeutics by 3,710.3% during the second quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock worth $33,000 after purchasing an additional 8,274 shares in the last quarter. Finally, Farther Finance Advisors LLC acquired a new position in shares of DiaMedica Therapeutics during the fourth quarter worth approximately $34,000. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.